PFWA
ALNY icon

Paces Ferry Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Paces Ferry Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-21
Closed -$3K – 153
2020
Q3 		$3K Buy
+21
New +$2.98K ﹤0.01% 575

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Paces Ferry Wealth Advisors's ALNY Position: Q4 2020 in Review

Paces Ferry Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 21 shares — an estimated $3K sold.

Paces Ferry Wealth Advisors first reported a position in ALNY in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

  • Paces Ferry Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Paces Ferry Wealth Advisors sold 21 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $3K.
  • Paces Ferry Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Paces Ferry Wealth Advisors's Alnylam Pharmaceuticals position peaked at $3K in Q3 2020.
  • 376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Paces Ferry Wealth Advisors's 13F filing for Q4 2020, filed 5 Mar 2021.